This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyers, P. A. Articles by Grier, H. E. Search for Related Content PubMed PubMed Citation Articles by Meyers, P. A. Articles by Grier, H. E. Related Articles Related Correspondence

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Paul A. Meyers, Cindy L. Schwartz, Mark D. Krailo, John H. Healey, Mark L. Bernstein, Donna Betcher, William S. Ferguson, Mark C. Gebhardt, Allen M. Goorin, Michael Harris, Eugenie Kleinerman, Michael P. Link, Helen Nadel, Michael Nieder, Gene P. Siegal, Michael A. Weiner, Robert J. Wells, Richard B. Womer, Holcombe E. Grier

From the Children's Oncology Group, Arcadia, CA

Corresponding author: Paul A. Meyers, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: meyersp{at}mskcc.org

Purpose: To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma.

Patients and Methods: Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 x 2 factorial design. The primary end points for analysis were EFS and overall survival.

Results: In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP (P = .08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03). The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96).

Conclusion: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.

Supported by Children's Oncology Group Grant No. CA98543. A complete listing of grant support for research conducted by Children's Cancer Group and Pediatric Oncology Group before initiation of the Children's Oncology Group grant in 2003 is available online at http://www.childrensoncologygroup.org/admin/grantinfo.htm.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• Osteosarcoma: The Same Old Drugs or More?
  Stefan S. Bielack, Neyssa Marina, Stefano Ferrari, Lee J. Helman, Sigbjørn Smeland, Jeremy S. Whelan, and Gregory H. Reaman
  JCO 2008 26: 3102-3103 [Full Text]
• Complexities in Interpretation of Osteosarcoma Clinical Trial Results
  Sally Hunsberger, Boris Freidlin, and Malcolm A. Smith
  JCO 2008 26: 3103-3104 [Full Text]

This article has been cited by other articles:

				S. S. Bielack, N. Marina, S. Ferrari, L. J. Helman, S. Smeland, J. S. Whelan, and G. H. Reaman Osteosarcoma: The Same Old Drugs or More? J. Clin. Oncol., June 20, 2008; 26(18): 3102 - 3103. [Full Text] [PDF]

				S. Hunsberger, B. Freidlin, and M. A. Smith Complexities in Interpretation of Osteosarcoma Clinical Trial Results J. Clin. Oncol., June 20, 2008; 26(18): 3103 - 3104. [Full Text] [PDF]